NCI目前對curcumin的已完成或仍在第三期臨床試驗中的結果/鏈接:

active clinical trials

closed clinical trials

來源: http://www.cancer.gov/drugdictionary?cdrid=43115

curcumin 

A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties. Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C. These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)